SCHEMBL15976002

SCHEMBL15976002

COc1ccc(-c2cc(C#N)c(N=[N+]=[N-])c(-c3ccc(C)cc3)c2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 3/20 0.40
PGR P06401 1/20 0.40
XDH P47989 1/20 0.38
ALKBH3 Q96Q83 1/20 0.37
KMT2A Q03164 4/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
ACHE P22303 1/20 0.36
MEN1 O00255 3/20 0.36
PRKAB2 O43741 1/20 0.35
PRKAG1 P54619 1/20 0.35
PRKAA2 P54646 1/20 0.35
PRKAA1 Q13131 1/20 0.35
PRKAG3 Q9UGI9 1/20 0.35
PRKAG2 Q9UGJ0 1/20 0.35
PRKAB1 Q9Y478 1/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
GABRA1 P14867 1/20 0.35
GABRG2 P18507 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15789658 0.95 PGR (0.43) ARPGRXDHKMT2ANPC1
SCHEMBL109789 0.77 AR (0.45) ARPGRXDHALKBH3KMT2A
SCHEMBL140629 0.71 PGR (0.49) ARPGRXDHKMT2ANPC1
SCHEMBL15832011 0.70 AR (0.51) ARPGRXDHALKBH3KMT2A
SCHEMBL8559564 0.70 AR (0.50) ARPGRXDHKMT2ANPC1
SCHEMBL8567177 0.70 AR (0.54) ARPGRKMT2ANPC1RAB9A
SCHEMBL3676881 0.66 ACHE (0.83) ALKBH3KMT2ANPC1RAB9AACHE
SCHEMBL295716 0.66 ACHE (0.83) ALKBH3KMT2ANPC1RAB9AACHE
SCHEMBL12714843 0.66 ACHE (0.83) ALKBH3KMT2ANPC1RAB9AACHE
SCHEMBL29662946 0.65 PGR (0.55) ARPGRKMT2AMEN1PRKAB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 AR 2395/4885PGR 1833/4885XDH 1318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.